Durability: Zenkuda’s ocular half-life in humans was calculated by measuring aqueous humor concentrations over time from patients in the Phase 1b Study 1 10 100 1000 10000 100000 0 4 8 12 16 20 24 28 • Aqueous humor samples were collected from 47 subjects in the Zenkuda Phase 1b study in patients with wet AMD, DME and RVO and were used to evaluate Zenkuda ocular half life in patients • Aqueous humor samples were collected at baseline and at Week 4, 12, 14, 16, 18, 20 and 24 and measured for Zenkuda concentrations • Samples collected between the last loading dose and the next re-dose were used to determine ocular half-life of Zenkuda Using Aqueous Humor Concentration of Zenkuda to Determine Ocular t 1/2 in Human Weeks Zenkuda aqueous humor concentration (ng/ml) 3 loading doses of intravitreal injections of 5 mg Zenkuda AH samples from Week 12 – 24 were used to determine Zenkuda t 1/2 Data from one individual patient from the Phase 1b study of Zenkuda is used to illustrate the methodology here. Patients received as-needed redosing after week 8 and aqueous humor samples collected after a re-dose were excluded from the analysis 14